Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Objective To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset...

Full description

Bibliographic Details
Main Authors: Ulrich A Walker, Jasmin B Kuemmerle-Deschner, Jeremy Levy, Eleni Vritzali, Hal M Hoffman, Tom van der Poll, PHILIP N HAWKINS, Hugh H Tilson, Stephanie Noviello
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001663.full

Internet

https://rmdopen.bmj.com/content/7/2/e001663.full

Similar Items